CA3183063A1 - Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof - Google Patents

Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof

Info

Publication number
CA3183063A1
CA3183063A1 CA3183063A CA3183063A CA3183063A1 CA 3183063 A1 CA3183063 A1 CA 3183063A1 CA 3183063 A CA3183063 A CA 3183063A CA 3183063 A CA3183063 A CA 3183063A CA 3183063 A1 CA3183063 A1 CA 3183063A1
Authority
CA
Canada
Prior art keywords
crystalline form
degrees
values
xrpd pattern
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183063A
Other languages
English (en)
French (fr)
Inventor
Qiangang ZHENG
Hao ZHUGE
Ye Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Etern BioPharma Shanghai Co Ltd
Original Assignee
Etern BioPharma Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etern BioPharma Shanghai Co Ltd filed Critical Etern BioPharma Shanghai Co Ltd
Publication of CA3183063A1 publication Critical patent/CA3183063A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3183063A 2020-06-18 2021-06-17 Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof Pending CA3183063A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020096778 2020-06-18
CNPCT/CN2020/096778 2020-06-18
PCT/CN2021/100673 WO2021254449A1 (zh) 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途

Publications (1)

Publication Number Publication Date
CA3183063A1 true CA3183063A1 (en) 2021-12-23

Family

ID=79268476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183063A Pending CA3183063A1 (en) 2020-06-18 2021-06-17 Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof

Country Status (8)

Country Link
US (1) US20230339975A1 (cg-RX-API-DMAC7.html)
EP (1) EP4169920A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532217A (cg-RX-API-DMAC7.html)
KR (1) KR20230026458A (cg-RX-API-DMAC7.html)
CN (1) CN115698007A (cg-RX-API-DMAC7.html)
AU (1) AU2021290733A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183063A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021254449A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860717A1 (en) * 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
JP2022506887A (ja) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
US20220073521A1 (en) * 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
KR20220054285A (ko) * 2019-06-28 2022-05-02 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
WO2021088945A1 (zh) * 2019-11-08 2021-05-14 南京圣和药业股份有限公司 作为shp2抑制剂的化合物及其应用
CN113754683A (zh) * 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用

Also Published As

Publication number Publication date
KR20230026458A (ko) 2023-02-24
EP4169920A1 (en) 2023-04-26
CN115698007A (zh) 2023-02-03
WO2021254449A1 (zh) 2021-12-23
US20230339975A1 (en) 2023-10-26
AU2021290733A1 (en) 2023-02-23
EP4169920A4 (en) 2024-08-07
JP2023532217A (ja) 2023-07-27

Similar Documents

Publication Publication Date Title
CN103298819B (zh) 6,7-不饱和-7-氨基甲酰基吗啡喃衍生物的晶体及其制备方法
IL178097A (en) Polymorphs of IMATINIB acid addition salts with tensulfonic acid
CN101676266B (zh) 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
EP2297092A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
KR101210361B1 (ko) 다형의 ｇａｂａａ 효능제
CN107163027A (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
AU2022239519B2 (en) Polymorphic forms of compound and preparation method therefor and application thereof
AU2018286057B2 (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
KR102847760B1 (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CA3183063A1 (en) Crystalline form of shp2 inhibitor, and composition thereof, preparation method therefor, and use thereof
JP2023513176A (ja) Ｅｐ４受容体アンタゴニストの多形体、その調製方法および用途
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
KR100909923B1 (ko) Ｎ-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-ｂ]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
EP2345649A1 (en) Benzimidazole compound in crystal form and salt thereof
CN102341392A (zh) 二氢苯并噁唑-6-基-乙酰胺衍生物的新的结晶水合物、无定形和多晶型形式及其制备方法
ES3036562T3 (en) Crystalline forms of pyrimidino diazepine derivative
CN111320596A (zh) 盐酸美呋哌瑞多晶型物及其制备方法
RU2792620C2 (ru) Кристаллическая форма ингибитора parp-1 и способ ее получения
WO2025256556A1 (zh) Protac嵌合化合物的固体形式、其制备方法、药物组合物和用途
WO2024146571A1 (zh) 用于预防和/或治疗神经退行性疾病的化合物
CN112334473A (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
HK40009119B (en) Crystal of benzofuran derivative free base and preparation method
HK40009119A (en) Crystal of benzofuran derivative free base and preparation method
CN111499610A (zh) 泊马度胺前体药物盐的多晶型物

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260223